C4 Therapeutics, Inc. CCCC
2.48 USD +0.04 (+1.64%)
Regular-session close
2.37 -0.11 -4.42%
After hours · Nov 20, 4:22 PM ET
2.32 Day range 2.55
1.69 52-week range 5.17
- YTD
- +29.84%
- 1 year
- +4.20%
CCCC revenue history
Revenue is income from the company’s ordinary business activities.
35,947,000 USD
FY 2025 · Period ended
Coverage: complete. Values in USD; not inflation adjusted.
Reporting currency is USD by the source’s USD conversion factor of 1; the source does not name the currency.
Scroll the table to see all values →
| Fiscal period | Period end | Revenue | YoY change | YoY % |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | 35,947,000 | 363,000 | 1.02% |
| FY 2024 | 2024-12-31 | 35,584,000 | 14,828,000 | 71.44% |
| FY 2023 | 2023-12-31 | 20,756,000 | -10,340,000 | -33.25% |
| FY 2022 | 2022-12-31 | 31,096,000 | -14,689,000 | -32.08% |
| FY 2021 | 2021-12-31 | 45,785,000 | 12,590,000 | 37.93% |
| FY 2020 | 2020-12-31 | 33,195,000 | 11,814,000 | 55.25% |
| FY 2019 | 2019-12-31 | 21,381,000 | 2,017,000 | 10.42% |
| FY 2018 | 2018-12-31 | 19,364,000 | Not available | Not available |
Percentage growth is shown only when the same fiscal period one year earlier has a positive value. Missing periods are not estimated.
Company-reported financial statements. Retrieved 2026-05-22T14:42:43.000Z. Retrieval time is not a report date.
Open full statementsUse Add to watchlist above to save this stock.
